Orchid Pharmaceuticals gets tentative nod for Sumatriptan Succinate

orchidOrchid Pharmaceuticals, a globally recognized, integrated pharmaceutical company, has notified that it has received tentative approval from the USFDA for its drug Sumatriptan Succinate tablets.

The drug is indicated to treat a migraine attack with or without the presence of an aura (visual disturbances, usually sensations of halos or flickering lights, which precede an attack).

Further, the Chennai-based Pharmaceutical major stated in a communiqué that the drug would be available in the strengths of 25 mg, 50 mg and 100 mg.

Shares of Orchid Chemicals & Pharmaceuticals are presently trading at Rs 102 on BSE, down Rs 7, or 6.22%. The scrip touched an intraday high and low of Rs 112 and Rs
99 respectively.